CD8A and hepatocellular carcinoma: Combination therapy using OX40 agonists and TLR9 agonists for HCC has shown promising results, promoting the activation of CD8+ and CD4+ T cells, suppressing regulatory T cells (Tregs) and myeloid-derived suppressor cells, and inducing immune memory responses (Zhou et al., 2021).